🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
7.35
+0.01 (0.14%)
At close: Nov 19, 2026, 4:00 PM EST
7.41
+0.06 (0.82%)
After-hours: Nov 19, 2026, 7:56 PM EST
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 17, 2026

Summary

KOMZIFTI reported strong Q3 launch growth, with combination use and frontline AML trials central to expansion. Darlifarnib has a potential salivary gland cancer registration path and RCC and pancreatic data expected in 2027.

David Dai
Biotech Analyst, UBS

Thank you, everyone, for joining us. My name is David Dai. I am a Biotech Analyst here at UBS. Welcome to the inaugural UBS conference here in London. It is our great pleasure to have Kura Oncology. We have the full team here with us. We have Jennifer Fulk, the new Chief Financial Officer, who is joining us here. Then we have Mollie Leoni, the Chief Medical Officer. Then we have Brian Powl, Chief Commercial Officer. So, we have the full team here on the panel. Then we are diving into some of the interesting stuff they are working on here. Given the fact that Kura, just for some background, for any investors here who are new to the story, Kura is a very interesting commercial stage company that has a menin inhibitor called ziftomenib, or KOMZIFTI, which treats relapsed/refractory AML.

They have been on the market since the beginning of this year, actually later toward the end of last year. So, it has been about three quarters. Most recently, the third quarter numbers look pretty compelling, especially given the quarter-over-quarter growth so far. Today, we will dive into that, some of the conversation there in terms of their commercial launch. At the same time, there is also other pipeline programs for KOMZIFTI in frontline AML. Outside of that, there is also a quite interesting farnesyl transferase inhibitor called darlifarnib that is in multiple different tumor types, including salivary gland cancer, which you are planning to do a registration trial for full approval soon. So, Mollie will spend some time talking about that as well. So, great discussion here, and let us just dive into that real quick.

So, maybe for the audience in this space, just give us a quick overview of the Kura story here. There are some key commercial and pipeline programs you guys are working on here.

Jennifer Fulk
CFO, Kura Oncology

First of all, David, thank you for having us. As you mentioned, Kura Oncology is now a fully integrated company. We have got capabilities across research, development, and commercialization. We are working on two products that have the potential to be multi-billion dollar commercial drugs. First is ziftomenib, as you said, our menin inhibitor. The commercial name is KOMZIFTI. We announced last week our third full quarter results. As you mentioned, we are delighted with growth across the KPIs, so new patient starts, prescriptions, net revenue. Everything is green there. We are really excited by that. In addition, we believe that the future of improving patient outcomes is really moving towards the earlier lines of therapy and in combination.

We also talked about, and Mollie will share more, that at ASH, we will have data importantly in FLT3 mutations, which FLT3 mutations occur in about a third of AML patients in total and half of NPM1 mutated patients. At the same time, we have our ongoing phase III trials, so in first line, in both intensive chemotherapy and non-intensive, so with Ven-Aza. We anticipate the initial top line results to be in 2028. We also have darlifarnib, it is our FTI program. Importantly, last week, we announced alignment with the FDA for a 40-patient registrational trial in HRAS mutant salivary gland cancer. So, a really exciting, quick-to-market possibility for our first full registration for darlifarnib. At the same time, we have a combination trial in renal cell carcinoma, where we anticipate the results from that in the second half of 2027.

We also have a combination trial in pancreatic cancer that Mollie will share more about, and we could see early results from that in the second half of next year. So, we have a very exciting 2027, particularly for darlifarnib. I will add, very importantly, that we are also well-capitalized and resourced to be able to deliver on the really important milestones we have coming up.

David Dai
Biotech Analyst, UBS

That is great. Yeah, I mean, just seems like there is a lot of stuff going on, a lot of milestones happening over the next 12 months. So, let us dive into KOMZIFTI first. The most recent third quarter numbers looks pretty compelling, especially given that far we are seeing a good number of new patient starts in NPM1 so far. Brian, maybe just help us understand a little bit more around what you are seeing in terms of adoption trends, and how should we think about over the next two or three quarters, the continued growth in new patient starts as well as revenue generation with KOMZIFTI?

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah, absolutely. Thanks, David, for the invitation here. It is great to be here. Yeah, so we have seen, as you said, some very robust growth quarter-over-quarter. It is our third full quarter of launch, where we reported $13.9 million in sales, which is about a little over 53% quarter-on-quarter growth. Our new patient starts were at about 150 new patient starts. That was about 35% quarter-on-quarter growth. Our overall total prescriptions were about 420, which is actually about a 65% growth overall. What that is showing us is that, as Jennifer said, all of the growth indicators are kind of going in the right direction. We are seeing kind of extending into new accounts. We grew our number of accounts that are prescribing KOMZIFTI by 40% over the quarter as well.

It is essentially giving us more depth into the market, and also for those accounts we have been treating, but also going into more accounts and getting more breadth going as well. I think this is a testament to the team's execution in a market that, as we know, is competitive, but it gives us an opportunity to really set the foundation for future growth, and we anticipate to see that continuing over the next several quarters as well.

David Dai
Biotech Analyst, UBS

Got it. Great. That is really helpful. Diving into a little bit more, it is interesting that you are already seeing pretty good new patient starts, given the fact that you are only being the third full quarter launch, right, compared to competitors. There are a couple of things I think you mentioned during the call that could drive the adoption trends. One is efficacy, safety, and then also ability to be able to combine, also dose convenience. What has been the most important driver of these adoption for physicians based on your feedback from physicians so far?

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah, absolutely. I think that it really, what we have heard is what we have been saying over time, right? It is that the combination of those really is what is setting KOMZIFTI apart. In order to drive uptake and prescriptions from physicians, you need to have efficacy, but you also have to have good tolerability and safety so the patients are able to stay on therapy. The combinability aspect is actually becoming a real pivot for the brand because we need to be able to combine with both concomitant medications like azoles and others without a lot of dose modifications, which makes things simple, but also being able to combine with other therapies like venetoclax, azacitidine, or as we will talk about a bit more about FLT3 as well. The simplicity of once-daily dosing is also useful for patients, and it is simple, I think.

That is something we have heard from not just physicians, but to the pharmacists, the other practitioners, nurses, and things as they treat it. So, it has really given us a strong foundation for us to grow. We think that not just sets us up in the relapse refractory setting, but also gives the opportunity as we move into frontline to really have a differentiated asset that would be able to benefit patients regardless of the combination that they can treat as well.

David Dai
Biotech Analyst, UBS

Combination is very interesting because you did mention that the combination % of patients are on combination have increased from 40% to 50% now, right?

How do you envision this number to kind of grow over time? Especially since you're going to have more data coming up at ASH, how do you think that's going to impact physician adoption? Do you think that could translate the data from ASH coming up in December could be able to translate to significant adoption in the next, say, two or three quarters?

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah, absolutely. I think that within this space, the NPM1-mutant population, as we entered into this space, we recognized that monotherapy is something that physicians needed to see activity within. But the feedback we heard from so many physicians was, "I really look forward to using this in combination." While our teams are, my commercial team particularly, are going to be promoting according to the label, the physicians start to see the familiarity of how to combine with KOMZIFTI, and that's why we've started to see that growth into that spontaneous use while used in combination. I think that the majority of the combination use has been in combination with venetoclax azacitidine, based on some of the data we published earlier this year in Blood, that demonstrated that the combination was safe, tolerable, and also improved on efficacy.

We're also seeing some FLT3 inhibitor combinations as well with gilteritinib. As you know, in the NPM1-mutated market, 30% of patients have an NPM1 mutation. About half of those have a FLT3 inhibitor as well. So without having clear data to show you can combine, physicians are typically going to sequence them. So they would treat with a FLT3 inhibitor first with gilteritinib, then followed by a menin inhibitor. But given that if we're able to show that we can combine, and that's what we're hoping to show with the data at ASH, it gives the opportunity for physicians to potentially get a deeper response earlier in the treatment course that allows for better outcomes for the patients as well.

David Dai
Biotech Analyst, UBS

Right. Yeah. In terms of the data, what's it going to show for KOMET-008, I believe, and this is going to be FLT3 plus KOMZIFTI. We did see some interesting data from ASH most recently, or ASH abstract, I would say. Mollie, can you help us to understand a bit more around what additional data should we be expecting from that KOMET-008 update, and any initial feedback from your firm, from physicians so far that they've said?

Mollie Leoni
CMO, Kura Oncology

Yeah, absolutely. We will be presenting the first really combinable FLT3 and menin inhibitor data come ASH, and we'll be doing it not only in the relapse refractory setting from our 008 trial, where we combine with gilteritinib plus ziftomenib, but we'll also be showing it in the frontline with quizartinib and a quadruplet with quizartinib 7+3 and ziftomenib. We're excited to be able to broaden that breadth, because as Brian said, it's half of your patients are going to have an FLT3 mutation as well. Being able to target two different problems causing the ultimate disease really helps fix the actual underlying issue versus just correcting after the problem's already happened.

We will be showing you from the gilteritinib, I'm especially excited about just the response rate, the overall durability of those responses, being able to get the patients to transplant, because generally by that relapse refractory course, the FLT3 mutant should be transplanted. It also does, even more importantly, argues against, I would say, sequencing and says that you should be using these drugs in parallel. Sequencing says you're counting on a relapse, and I'd rather avoid the relapse altogether. I think you'll see that. Then we'll have some interesting findings about how to even improve the responses more.

Similarly with quizartinib in the frontline, you'll be able to see some early look at our dose escalation data, where we've been successfully able to escalate all the way up without dose-limiting toxicities, and these patients have 100% CRc rate. We'll watch that story evolve over time as well.

David Dai
Biotech Analyst, UBS

That's really good. Then, come back to a little bit more around the adoption 3Q. We did see. New patient starts versus the total script seems to be. It seems like there's more total scripts available for third quarter than new patient starts, which means there's more patients coming back for repeat dose right here, right, Brian? So, help us understand a little bit more around what do you see as sort of like the duration of therapy right now? Then as you're thinking through the combo, adding this on top of gilteritinib and as well as other combination strategies, how do you think the duration of response or duration of therapy would evolve over time?

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah. I think that you're right. I think as KOMZIFTI, when we first started to be used in the market, as we got to the market a year ago, a lot of the patients were probably in that monotherapy later line of treatment. As I think physicians get more used to treatment, you started to see more of this combination use. The combination use is probably what may help to improve on the durability. We're three full quarters in, and we had shared before, we think this overall market is about a $350 million-$400 million market with about six months of therapy as our expectation. And we're starting to see that, but we still need a little bit more time as patients come on.

As you see that with the total prescriptions increasing faster than the new patient starts, that tells you that patients are staying on therapy. We need a little bit more time for us to see how that gets into a steady state. But our expectation is that patients who are able to get on and stay on therapy when they benefit, would improve that. So, the combinations are likely a good opportunity for us to see increases in that overall duration.

David Dai
Biotech Analyst, UBS

Got it. That's really helpful. Great. So we should expect the duration of therapy will increase, right, with additional combos?

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah. I mean, we need to see it read out by the patients. But yeah, that's the thinking within a combination.

David Dai
Biotech Analyst, UBS

Great. Speaking of ASH, one of the things that will get quite a bit of investor inbound was the Johnson & Johnson data, or ASH abstract, where they showed higher CR/CRh, almost doubling of what we saw with KOMZIFTI here. So maybe, Mollie, just help us understand a little more around what do you think about the data overall? How do you think this dataset is going to impact the competitive landscape? Or what are investors getting wrong here?

Mollie Leoni
CMO, Kura Oncology

Yeah. I think it's very important to note that we still don't know what the Johnson & Johnson data is for monotherapy. They showed a very cherry-picked subgroup analysis. They left out a large majority of the patients. And realistically, if you do the math yourself, you probably get to the point where the efficacy is probably similar to the other menin inhibitors that are out there. And that's really the story, is that menin inhibitors as a whole kind of act the same, just with different safety and tolerability profiles. But I kind of don't even think about the monotherapy world anymore, because we've moved on since then as a field. We are in the combination setting, and that's why it's so important for us to be sharing the combination data at this point, because AML is a combination treatment disease.

If we started again today, I probably would never do monotherapy. I'd just go straight to combination. But we're already heavily into our combinations in the frontline, the relapse refractory setting, and taking it across all the different subtypes of both intensive chemos and non-intensive chemos and FLT3s, and also broadening even the subtypes that are eligible. So it's beyond NPM1, beyond KMT2A rearranged. We're hitting DNMT3A, we're hitting IDH, we're hitting all these other SETD2 and RUNX1 mutations that are so important and tough to treat with a menin inhibitor. And so we'll continue to branch out and share more and more of our combination data, and I think that that's what you'll see the field shift to. It won't be a monotherapy story anymore.

David Dai
Biotech Analyst, UBS

Interesting. Speaking of the combination, we did notice for the Johnson & Johnson bleximenib, they did have sort of slightly higher heme tox with about 35% or so of Grade 3 cytopenia and neutropenia. Do you feel, based on this profile, they will have a hard time combining with other therapies like venetoclax? Because these are already myelosuppressive drugs, or even moving to frontline with intense chemotherapy, the 7+3, they are going to have an issue with combining.

Mollie Leoni
CMO, Kura Oncology

They will have a harder time, for sure. Because if there were no other options, well, then you would take that risk with the cytopenias, with the increased bleeds, with the increased infections, and with the increased risk of early death, realistically. But there are other options, and we have shown that KOMZIFTI does not have the same liabilities as the other molecules that are out there. We do not have the same level of cytopenias. Once the patient has cleared the disease, we have no issues with thrombocytopenia, whereas you see competitors actually having to either discontinue or decrease the dose, even in a monotherapy post-transplant maintenance setting. So I think that it is not going to be the best option for patients to have something that causes more cytopenias.

David Dai
Biotech Analyst, UBS

Got it. Great. It is a great segue to move to the frontline in AML. I feel like it is a bigger market compared to relapse refractory AML. You have two phase III trials right now. Well, sort of two phase III trials for both the non-intense chemotherapy and also with the intense chemotherapy combo, right, in those settings. Please help us understand a little more around those phase III trial designs. Also you are using surrogate endpoint. Help us understand a little more around that. Then how are the enrollment going so far for those three phase III trials?

Mollie Leoni
CMO, Kura Oncology

Yeah. So this is our KOMET-017 trial. Rather than do the trial separately, meaning non-intensive in one and intensive in another, or one with a cooperative group and one ourselves, both are corporate-sponsored trials in one protocol. So that means we might have to get up and running one time, and it makes it much more convenient so that the physician has one study when a patient walks into his office with a menin-dependent leukemia, he can put them into whatever appropriate treatment there is without having to do multiple protocols. So it is going very well. Thankfully, we did our 007 trial, which was the phase I, fairly large trial though, where we got a true idea of what the enrollment rate would be, and it is holding through very tightly.

As we've said, we will be able to share the first results from the frontline registrational trial in 2028, and again, we're still quite certain of that. That will be our accelerated approval endpoint for the intensive chemotherapy combination, and that's CR MRD negative rates. The full approval will be with an EFS endpoint. Our non-intensive chemotherapy will follow closely behind, and that'll have accelerated endpoint of the CR rate with OS as the full approval endpoint.

David Dai
Biotech Analyst, UBS

Got it. For both endpoints, I think one of the debates is around what is considered meaningful here, right? Anything you can share, Mollie, in terms of what kind of benchmark or what would be considered meaningful from the FDA standpoint in terms of MRD negative CR for the intense chemotherapy cohort and also the CR rates for the other cohorts?

Mollie Leoni
CMO, Kura Oncology

Yeah. So one of the reasons we chose the MRD negative CR rate is because there's a lot more room for improvement there with 7+3. For just reference sake, the MRD negative or positivity is what dictates kind of the patient's next step in their treatment paradigm. So if they're going to go to transplant or not, or if they need to stay on maintenance, et cetera. So we chose MRD negativity in the bone marrow after two cycles as our endpoint.

You would expect a 7+3 alone in the NPM1 mutants to see about 44% of the patients with a negative MRD in the bone marrow at that point. So there's clearly a lot of room for improvement there. Clinically meaningful, you'd expect 10%-15% to be a clinically meaningful bump within that patient population. CR for Ven-Aza, similarly, there's a lot of room for improvement there.

You see 70%-80% complete response rate. We think we can make a meaningful improvement there as well with another 10%-15% boost.

David Dai
Biotech Analyst, UBS

And you already show that from the KOMET-007 study, right?

Mollie Leoni
CMO, Kura Oncology

We're very confident based on what we saw in 007 that we designed 017 correctly.

David Dai
Biotech Analyst, UBS

Yeah. Right. Then there's quite a bit of translation from this, from 007 to 017 based on the frontline patients' characteristics. Can you share us around how confident you are about translation?

Mollie Leoni
CMO, Kura Oncology

So far, it has been I'm so glad that we did a larger phase I-B, because we've had hundreds of patients with data to really understand which patients were going to what types of therapies and what was the best way to really expect the enrollment to go. And it's really been playing exactly as we expected. You see more into your 7+3 than your Ven-Aza. I think that'll always be because it's just a different therapy with different goals. And as I said, we expect 2028 to be a solid year for being able to share the data.

David Dai
Biotech Analyst, UBS

Got it. Thinking more broadly than your frontline AML, in 2028 and beyond, it is probably going to be multiple different competitors in that space. We have KOMZIFTI likely kind of have your competitors from Syndax and from Johnson & Johnson. How do you envision KOMZIFTI's profile to be able to compete against the other players in the space in frontline?

Mollie Leoni
CMO, Kura Oncology

I think it is exactly as you pointed out. First and foremost, it will be about the cytopenias. These patients, they cannot be put in longer risk than they need to. What we have shown with each data set we have put out is that we have count recoveries that are similar to the background rates that you would see with either Ven-Aza or 7+3 or gilteritinib or quizartinib, not really adding to that. So the patients are able to recover their counts within that first cycle pretty easily. So that is huge. The second is we do not have severe QT prolongation as part of our drug profile. We have it as a warning and precaution, but it is only because we had a monotherapy single-arm trial rather than something randomized to show the difference.

As we get more and more into randomized data, I think you will see that there is no QT signal there. Differentiation syndrome, it is actually a good problem to have once you understand how to control it. We control it best through combination use, and we do not see any difficulties managing differentiation syndrome. Now, I think it is different from our competitors who see problematic cytopenias, who see problematic QT prolongation, and who actually, at least for J&J, even in combination setting, have fatal differentiation syndrome. So truly, we have a compound that is safer and easier to use.

David Dai
Biotech Analyst, UBS

Got it. Safe, easier to use, and also potential combo benefit there. That would be the key advantages in frontline AML.

Mollie Leoni
CMO, Kura Oncology

Yes.

David Dai
Biotech Analyst, UBS

Great. Okay. Fantastic. We're definitely looking forward to that 2028 update, right, from you guys. Okay, moving on to darlifarnib, which I do want to spend some time just thinking about this. I do feel like this is an interesting program, quite underappreciated by investors. We've seen some data over the past 12 months or so for darli in combination with cabozantinib as well as in other drugs. Maybe, Mollie, just help us understand more around the data we've seen so far, and then how should we think about this program going forward?

Mollie Leoni
CMO, Kura Oncology

Yeah. So we're really excited about darlifarnib. It is our farnesyl transferase inhibitor, our second generation. Many remember tipifarnib, but now we've moved on and we actually have a much better molecule. Currently, we're developing it in both combination setting and as a monotherapy. We recently announced that we have a path to approval as a monotherapy with FDA for a 40-patient study in a salivary gland cancer patient population. Very high unmet need, so it will be a very addressable patient population. And we've already shown data that would exceed what you'd expect these patients to experience for a response rate with currently available therapies.

We're also developing it in the renal cell carcinoma space in combination with cabozantinib, and we're in our phase I-B, so producing a lot of data there that we hope to finish enroll it by the first half of next year, and then be able to share data by the second half. Also very focused on our PDAC combination. We will be starting a combination with daraxonrasib. And what's de-risking for that for us is that we already did a combination with adagrasib in PDAC, as well as a few other indications, and saw remarkable response rates. Small data sets, but everything trending in the direction of darlifarnib being able to augment and make these other drugs better.

David Dai
Biotech Analyst, UBS

What's the mechanism behind that combo benefit?

Mollie Leoni
CMO, Kura Oncology

To make it simple in these various combinations, it's an mTORC1 inhibitor. It helps selectively inhibit that molecule that a lot of cancers use to escape the targeted therapy that they're on. It'll upregulate their MAP kinase usage in order to keep the cancer prosperous, and our drug comes in and hits the pathway at another spot that kind of knocks it out and prevents it from either escaping a response or never initiating a response.

David Dai
Biotech Analyst, UBS

Got it. For the first combo, which is cabozantinib plus darlifarnib, you're going to have a trial called FIT-001. What kind of setting are you thinking about in terms of is this going to be in CCRCC? What setting do you feel makes more sense to move that combo into right now?

Mollie Leoni
CMO, Kura Oncology

Yeah. Think of it in different ways. I think the third line is a very easy setting for us to move into. But when we say third line in RCC, that means post-IO, post-TKI. I think our data will actually also be supportive of moving into a second line setting, which is really just post-IO. So you're going to get a mixture of those patient populations. But the ultimate goal should be post-IO, which equivalent to more like a second line.

David Dai
Biotech Analyst, UBS

Yeah, got it. What's sort of the benchmark for clinical meaningful ORR, DOR, PFS we should be thinking about in those two settings?

Mollie Leoni
CMO, Kura Oncology

Especially in the third line, you are thinking of a rather low response rate, so you get probably 20%-30% response rate, and a PFS around eight months. We have already kind of exceeded that with our data. We have shown 33%-50% response rate and a 13-month PFS. That is why we feel so confident about the second line. I think if we get response rates up into the 50% range, that is when we will start talking about that we would be sliding directly into second line.

David Dai
Biotech Analyst, UBS

Got it. Just in terms of the market opportunity here, I think this helps understand a little more around what exactly will be considered, how big is the CCRCC market especially in second and third line, in terms of dollar amount?

Brian Powl
Chief Commercial Officer, Kura Oncology

Yeah, the third line, I think, as it gets characterized, is probably about the, let us say, just about $900 million, $1 billion market opportunity. When you go into the second line, it definitely rises up more into the multi-billion dollar opportunity to kind of build through. It all depends, I think, on the data, which are combinations, and how to make sure that flows. But as we know, cabozantinib is kind of the leading TKI, and being able to combine and make that better gives an opportunity for significant market potential.

David Dai
Biotech Analyst, UBS

Got it. So $1 billion, $1.5 billion or more market opportunity in those CCRCC settings there. Quite a bit of excitement there, for sure. One last question just on darlifarnib. Some of the investors were kind of pushing back on the neutropenia, right? So we are seeing with the company, with cabo and darlifarnib combo, and what are some of the things you are thinking about in terms of mitigation strategies for neutropenia?

Mollie Leoni
CMO, Kura Oncology

Obviously, the data that we've shared up till now was generated in a dose escalation setting, which means you couldn't prophylax for things like neutropenia. Now they can, now they do. So I expect to see the rates of neutropenia decrease. Some are doing it only when they see the event, some are doing it before the event happens. But I think more important than even the ability to prophylax is the fact that we weren't seeing translation of these neutropenias into adverse events. They weren't becoming infections. So already, it was more of a lab finding than an issue. Now we'll really be able to prevent it from becoming an issue for these patients. That's what's hardest and most important for the population.

David Dai
Biotech Analyst, UBS

Yeah. Then just maybe one last question before we end here. Just in terms of the near-term catalysts or milestones over the next six to 12 months, how should we think about these things that we should be focusing on here?

Jennifer Fulk
CFO, Kura Oncology

Yeah. A couple things that you heard us talk about. For ziftomenib, look for continued execution in the commercial setting. Both in terms of growth and continuing leadership there, but also supported by the combination data that we talked about. As Mollie mentioned, the different combination settings and the data we're creating really is set to address up to 50% of the AML market.

So, we expect that to be a milestone. Of course, our phase III trial that you should expect to see continued progress on enrollment. So really setting up ziftomenib to be a foundational therapy in AML. Then as we said, darlifarnib, 2027 is a really important year for all the reasons we talked about. Initiation of a potential registrational study, as well as RCC phase I-B data in the second half year, and potentially early data in pancreatic cancer.

So really, really exciting year for us ahead.

David Dai
Biotech Analyst, UBS

Great. Lots of key updates and a catalyst-rich 2027 and 2028 as well. Looking forward to more updates. Thank you so much for joining this.

Jennifer Fulk
CFO, Kura Oncology

Thank you.

Brian Powl
Chief Commercial Officer, Kura Oncology

Thank you, David.

David Dai
Biotech Analyst, UBS

Take care, everyone.